DELCATH SYSTEMS, INC.
Nasdaq · Surgical & Medical Instruments & Apparatus
Company Overview
A concise company profile alongside the latest public filing activity.
Delcath Systems develops and markets percutaneous hepatic perfusion systems used to administer chemotherapy directly to the liver while filtering drugs from the blood before it returns to systemic circulation, primarily for treating liver-dominant cancers such as metastatic uveal melanoma.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Martell Bridget ADirector | Sell | $446K | 20,570at $21.66 | Nov 12, 2026 |
| Martell Bridget ADirector | Sell | $43K | 1,930at $22.26 | Nov 12, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable DCTH activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.